Ubiquitin-dependent recruitment of SLFN11 to chromatin is regulated by deubiquitinase and RNF168

This study reveals that the deubiquitinase inhibitor VLX-1570 and DNA damage both trigger the ubiquitin-dependent recruitment of SLFN11 to chromatin via RNF168-mediated K27-linked polyubiquitination of specific lysine residues in its linker domain, leading to transcriptional suppression at promoter regions.

The Gist

The Big Picture: A Security Guard with a New Job

Imagine your cell's DNA is a massive, busy library. Inside this library, there is a very strict security guard named SLFN11.

For a long time, scientists knew that when the library gets damaged (like a fire or a broken shelf caused by chemotherapy drugs), SLFN11 rushes to the specific spot of the damage to lock down the area and stop the chaos. This is its "emergency mode."

But this new study discovered something surprising: SLFN11 has a second job. It can be called to patrol the entire library, not just the damaged spots, to shut down the reading rooms (transcription) and stop the library from working.

The Discovery: The "De-Tagging" Sabotage

The researchers were looking for drugs that could trick SLFN11 into going to work. They tested 162 different cancer drugs on cells.

They found that a specific type of drug called a DUB inhibitor (Deubiquitinase inhibitor) was the most effective at calling SLFN11 to the DNA.

The Analogy:
Think of proteins in the cell as packages. To get a package delivered to a specific address (the DNA), it needs a special shipping label called Ubiquitin.

• DUBs (Deubiquitinases) are like "label removers." They take the shipping label off packages so they don't get delivered.
• DUB Inhibitors are like "glue" that jams the label removers.

When the researchers used these inhibitors, the "label removers" got stuck. Suddenly, the cell was covered in packages with shipping labels still attached. This massive buildup of "labeled" proteins acted like a siren, screaming at SLFN11: "Get to the DNA! Now!"

The Difference: Emergency vs. Global Shutdown

The study found two very different ways SLFN11 gets to the DNA:

1. The Old Way (Chemotherapy): When DNA is physically broken (like a broken shelf), SLFN11 runs to that specific crack. It's like a firefighter rushing to a specific burning room.
2. The New Way (DUB Inhibitors): When the "label removers" are jammed, SLFN11 doesn't just go to one spot. It spreads out and covers the whole library. It's like a security guard locking down every single door in the building, not just the one with the fire.

Key Finding: This new "global lockdown" happens even if there is no fire (no DNA damage). It happens because the cell is confused by all the extra shipping labels.

The Mechanism: The "K27" Tag and the "RNF168" Manager

The researchers wanted to know how SLFN11 knows to go to the DNA. They found the specific instructions:

• The Tag: SLFN11 needs a specific type of shipping label called K27-linked Ubiquitin. Think of this as a "VIP Access Pass" that only allows SLFN11 to enter the DNA area.
• The Manager: There is a specific protein manager named RNF168. Its job is to attach these VIP passes to SLFN11.
• The Location: The researchers found that RNF168 attaches these passes to the "middle section" of SLFN11 (like a belt or a linker). If you cut off this middle section or change the spots where the passes are attached, SLFN11 loses its VIP pass and can't get into the DNA area.

The Analogy:
Imagine SLFN11 is a delivery driver. RNF168 is the dispatcher who puts a special "VIP" sticker on the driver's chest. Without that specific sticker, the driver is stopped at the gate. The DUB inhibitors cause a traffic jam of stickers, forcing the dispatcher to put VIP stickers on SLFN11, sending it straight to the DNA.

What Happens Next?

Once SLFN11 is all over the DNA (thanks to the DUB inhibitors), it does two things:

1. It opens the doors: It makes the DNA more accessible (like opening all the library books).
2. It shuts down the reading: It stops the cells from making new RNA (the instructions for making proteins).

This is actually a double-edged sword. While it stops cancer cells from growing, it also stops them from functioning normally, which can lead to cell death.

Why Does This Matter?

1. New Cancer Treatments: This explains how certain drugs (DUB inhibitors) work. They don't just break DNA; they trick the cell's security system into a total shutdown.
2. Understanding the Guard: We now know SLFN11 isn't just a "damage repair" guy; it's also a "gene regulation" guy. It helps control which genes are turned on or off.
3. The "Middle" is Important: Scientists used to focus on the ends of the SLFN11 protein. This study shows that the "middle" part is actually the control center for its movement.

Summary in One Sentence

By jamming the cell's "label-removing" machines, researchers found they can force the protein SLFN11 to flood the DNA with a specific "VIP tag" (K27 ubiquitin) created by a manager named RNF168, causing the cell to shut down its gene activity and potentially die.

Technical Summary

1. Problem Statement

Schlafen 11 (SLFN11) is a critical determinant of cellular sensitivity to DNA-damaging agents (DDAs) and replication stress. While it is well-established that SLFN11 is recruited to stressed replication forks (co-localizing with RPA) to induce cell death, the molecular mechanisms governing its recruitment to non-replicating chromatin regions (such as promoters) remain unclear. Furthermore, the role of post-translational modifications (PTMs), specifically ubiquitylation, in regulating SLFN11's chromatin association and transcriptional regulatory functions has not been elucidated.

2. Methodology

The authors employed a multi-faceted approach combining high-throughput screening, biochemical assays, and genomic profiling:

• High-Throughput Imaging (HTI) Screen: A screen of 162 oncology-focused compounds was performed in U2OS cells with doxycycline-inducible SLFN11 expression. Cells were pre-extracted to isolate chromatin-bound proteins, and SLFN11 recruitment was quantified via automated microscopy.
• Cellular Models: Utilization of U2OS (inducible SLFN11) and DU145 (endogenous high SLFN11) cell lines.
• Pharmacological Inhibition: Use of DUB inhibitors (VLX-1570, PR-619, WP1130), the ubiquitin-activating enzyme inhibitor TAK-243, and proteasome inhibitors (MG132).
• Biochemical Assays:
  • Immunoprecipitation (IP) & Co-IP: To verify physical interactions between SLFN11 and E3 ligases (RNF168).
  • Ni-NTA Pull-downs: To assess SLFN11 ubiquitylation status using His-tagged ubiquitin.
  • Site-Directed Mutagenesis: Generation of SLFN11 lysine-to-arginine (K-to-R) mutants to map ubiquitylation sites and ubiquitin linkage-specific mutants (K27R, K48R, etc.) to determine chain types.
  • Proximity Ligation Assay (PLA): To visualize endogenous SLFN11-RNF168 interactions in situ.
• Genomic Profiling: Chromatin Immunoprecipitation sequencing (ChIP-seq) to map SLFN11 and H3K27ac occupancy across the genome.
• Transcriptional Analysis: 5-ethynyl uridine (EU) pulse-labeling to measure nascent RNA synthesis.

3. Key Contributions & Results

A. DUB Inhibitors Drive Massive SLFN11 Chromatin Recruitment

• Discovery: The HTI screen identified deubiquitinase (DUB) inhibitors (specifically VLX-1570, PR-619, and WP1130) as the most potent inducers of SLFN11 chromatin recruitment, surpassing traditional DDAs like camptothecin (CPT).
• Distinct Localization: Unlike CPT, which induces discrete SLFN11 foci at replication forks (RPA-dependent), DUB inhibitors induce a pan-nuclear, diffuse recruitment of SLFN11.
• Independence from DNA Damage: This recruitment occurs rapidly (within 30 minutes) and without detectable DNA damage markers (no $\gamma$H2AX foci) and is largely independent of RPA2 foci.
• Ubiquitylation Dependency: The recruitment is strictly dependent on ubiquitylation, as it is abolished by the UBA1 inhibitor TAK-243.

B. Recruitment to Active Promoters and Transcriptional Suppression

• Chromatin State: DUB inhibitor-induced SLFN11 recruitment correlates strongly with H3K27ac (a marker of active transcription and open chromatin) and does not associate with heterochromatin (H3K27me3).
• Genomic Mapping: ChIP-seq revealed that SLFN11 is preferentially enriched at promoter regions (approx. 80% overlap with H3K27ac peaks).
• Functional Consequence: The recruitment of SLFN11 to these active promoters leads to a significant suppression of nascent RNA synthesis, suggesting a role in transcriptional regulation distinct from its replication-blocking function.

C. Mechanism: RNF168-Mediated K27-Linked Ubiquitylation

• E3 Ligase Identification: The study identified RNF168 as the specific E3 ligase responsible for SLFN11 ubiquitylation. Physical interaction was confirmed via IP and PLA.
• Linkage Specificity: SLFN11 ubiquitylation is driven by K27-linked polyubiquitin chains. Mutating the K27 residue in ubiquitin (K27R) drastically reduced SLFN11 ubiquitylation, whereas K11R/K48R mutations increased it, suggesting K27 linkage is a prerequisite or upstream regulator.
• Target Sites: The ubiquitylation sites were mapped to the middle linker domain of SLFN11, specifically lysine residues K390, K391, and K429.
• Functional Validation:
  • Depletion of RNF168 or expression of the SLFN11-3KR mutant (K390R/K391R/K429R) significantly impaired SLFN11 chromatin recruitment in response to both DUB inhibitors and CPT.
  • This confirms that RNF168-mediated K27 ubiquitylation is essential for loading SLFN11 onto chromatin.

4. Significance

• Paradigm Shift: The study expands the functional scope of SLFN11 beyond a replication stress sensor. It reveals a ubiquitin-dependent mechanism where SLFN11 is recruited to open, transcriptionally active chromatin to regulate gene expression, independent of DNA double-strand breaks.
• Novel Regulatory Axis: It establishes a critical regulatory axis: DUB inhibition $\rightarrow$ RNF168 activation $\rightarrow$ K27-linked ubiquitylation of SLFN11 $\rightarrow$ Chromatin recruitment.
• Therapeutic Implications:
  • DUB Inhibitors: The findings suggest that DUB inhibitors (like VLX-1570) may exert anti-cancer effects partly by forcing SLFN11 into chromatin, thereby suppressing transcription and inducing cell death, particularly in SLFN11-high tumors.
  • Biomarkers: SLFN11 status and the ubiquitin signaling pathway could serve as biomarkers for predicting response to DUB inhibitors.
  • Mechanistic Insight: Understanding the K27-linkage dependency offers new targets for modulating SLFN11 activity in cancer therapy, potentially overcoming resistance mechanisms associated with SLFN11 deficiency.

In summary, this paper elucidates a previously unknown, ubiquitin-dependent pathway where RNF168 mediates K27-linked ubiquitylation of SLFN11, driving its recruitment to active promoters to suppress transcription, a process distinct from its classical role in replication fork stalling.